Introduction {#s1}
============

The discovery of vitamin D is one of medicine's great achievements. Vitamin D is classed as a vitamin even though recent findings showed that vitamin D is truly a prohormone \[[@R01]\]. If we step away from the fact that vitamin D is a vitamin and look at the bigger picture, it has huge potential in many areas.

Despite all the positive evidence emerging about the beneficial effect of vitamin D on various diseases and its need for optimal health, we still find that many people are vitamin D deficient. Vitamin D deficiency can aggravate many diseases, is linked to predisposition of diabetes and may play a role in the development of diabetes \[[@R02], [@R03]\]. Studies show that vitamin D affects insulin sensitivity and insulin secretion, and vitamin D deficiency may also contribute to impaired glucose tolerance.

Low levels of 25-hydroxyvitamin D (25(OH)D) have been documented among inhabitants of the Middle East where people cover themselves from the harsh sun \[[@R04], [@R05]\]. This lifestyle habit and their natural diet of low vitamin D consumption may cause poor glucose control in diabetic patients.

Purposes {#s1a}
--------

The purposes of this study were to examine the association between serum 25(OH)D and glycosylated hemoglobin (HbA1c) levels, to test the hypothesis that lower 25(OH)D levels are associated with poorer glucose control in diabetes mellitus (DM) patients, and to investigate the effect of vitamin D supplementation on HbA1c levels in DM patients. Accordingly, we propose to perform a prospective cohort study of prevalence of vitamin D deficiency in diabetic patients as well as correlation of deficiency correction of vitamin D on patients with diabetes in Saudi Arabia.

Materials and Methods {#s2}
=====================

This was a prospective observational cohort study of all patients with type 1 and type 2 diabetes aged 12 years and above (younger patients were seen by pediatric endocrinologists), who attended the outpatient clinics of a tertiary center in Riyadh from 2015 onwards. After exclusion of subjects with other comorbidities like parathyroid disease, those currently using vitamin D or calcium and pregnancy or breastfeeding mothers, the datasheet consisted of 1,000 subjects available for the present analysis. The study was approved by the Institutional Review Board (IRB) and informed consent was obtained from all participants of the study.

Variables studied {#s2a}
-----------------

The following variables were collected from the medical record: age, sex, type of diabetes, HbA1c result, free thyroxine (FT4), thyroid-stimulating hormone (TSH), parathyroid hormone (PTH), vitamin D level and corrected calcium level. Baseline HbA1c and vitamin D levels were recorded prior to supplementation and after a period of 9 months of supplementation with vitamin D, HbA1c and vitamin D levels were recorded once again. Patients were informed about being supplemented with vitamin D. Patients were continued with usual treatment. The serum level of 25(OH)D was measured by competitive protein-binding assay using appropriate kits (Immunodiagnostic, Bensheim, Germany). HbA1c was measured using high-performance liquid chromatography.

Grouping of patients {#s2b}
--------------------

All patients were divided into four groups according to their vitamin D level as follows: severe deficiency (\< 20 nmol/L), moderate deficiency (20 - 49.99 nmol/L), insufficiency (50 - 74.99 nmol/L) and sufficiency (≥ 75 nmol/L). An association between 25(OH)D and HbA1c was tested for the 1,000 patients categorized according to their vitamin D status. At follow-up, the patients were compared based on the HbA1c and vitamin D level at baseline and at follow-up. All participants were receiving their regular treatment with either insulin or oral hypoglycemic agents or both. After follow-up the patients were again regrouped and analyzed to find out if any patients were still deficient in vitamin D.

Statistical methods {#s3}
===================

Continuous variables are represented as mean ± SD and percentages. One-way ANOVA or unpaired *t*-test was used to analyze the difference between means. The Chi-square test was used for categorical data comparison. Pearson correlation coefficients between continuous variables were used as a measure of association. The data obtained were statistically analyzed using SPSS version 16.0. The significance level for results was set as P \< 0.05.

Results {#s4}
=======

Characteristics of study population {#s4a}
-----------------------------------

All patients completed the study. The baseline mean HbA1c value was 10.55 ± 2.59 and was 7.7 ± 1.6 at follow-up. The baseline mean vitamin D value was 40.09 ± 23.13 and was 80.51 ± 29.77 at follow-up. There were almost twice as many females to males (60.3% vs. 39.7%) and twice as many type 2 DM patients to type 1 DM patients (66.2% vs. 33.8%). Other baseline characteristics are shown in [Table 1](#T1){ref-type="table"}.

###### Baseline Characteristics of the Study Participants

  Baseline characteristics                              
  ----------------------------------------------------- ----------------
  Age (years) (mean ± SD)                               43.124 ± 19.46
  HbA1c pre-supplementation (%) (mean ± SD)             10.55 ± 2.58
  Vitamin D pre-supplementation (nmol/L) (mean ± SD)    40.09 ± 23.13
  HbA1c post-supplementation (%) (mean ± SD)            7.70 ± 1.61
  Vitamin D post-supplementation (nmol/L) (mean ± SD)   80.5 ± 29.77
  TSH (mIU/L) (mean ± SD)                               2.89 ± 2.48
  FT4 (pmol/L) (mean ± SD)                              15.89 ± 8.08
  C.Ca (mmol/L) (mean ± SD)                             2.32 ± 0.13
  Male, N (%)                                           397 (39.7%)
  Female, N (%)                                         603 (60.3%)
  T1DM, N (%)                                           338 (33.8%)
  T2DM, N (%)                                           662 (66.2%)

HbA1c: glycated hemoglobin; TSH: thyroid-stimulating hormone; FT4: free thyroxine; C.Ca: corrected calcium; T1DM: type 1 diabetes mellitus; T2DM: type 2 diabetes mellitus.

Characteristics based on vitamin D value {#s4b}
----------------------------------------

In order to further characterize the relation between HbA1c and vitamin D, we grouped the patients on the basis of vitamin D levels, there was a significant difference in the age of the patients, and the patients who were older had higher levels of vitamin D (P = 0.0001). Age and vitamin D levels at baseline and at follow-up were significantly correlated (0.24, P \< 0.00001 and 0.2, P \< 0.00001, respectively) ([Table 2](#T2){ref-type="table"}).

###### Baseline Characteristics Grouped on Basis of Vitamin D Levels

  Baseline characteristics                              Vitamin D group   P value                                          
  ----------------------------------------------------- ----------------- --------------- --------------- ---------------- ----------
  Age (years) (mean ± SD)                               38.61 ± 18.88     41.0 ± 19.33    49.96 ± 17.5    51.64 ± 55.5     0.0001
  HbA1c pre-supplementation (%) (mean ± SD)             10.62 ± 2.45      10.86 ± 2.6     9.93 ± 2.56     9.81 ± 2.52      0.0001
  Vitamin D pre-supplementation (nmol/L) (mean ± SD)    14.17 ± 3.88      33.58 ± 8.29    60.33 ± 7.03    91.75 ± 15.14    0.0001
  HbA1c post-supplementation (%) (mean ± SD)            7.63 ± 1.61       7.89 ± 1.70     7.37 ± 1.39     7.4 ± 1.16       0.0001
  Vitamin D post-supplementation (nmol/L) (mean ± SD)   68.11 ± 29.02     74.46 ± 25.82   92.27 ± 20.02   118.66 ± 31.12   0.0003
  TSH (mIU/L) (mean ± SD)                               3.15 ± 3.33       2.96 ± 2.42     2.6 ± 1.99      2.52 ± 1.46      0.0001
  FT4 (pmol/L) (mean ± SD)                              15.44 ± 2.73      16.09 ± 10.42   15.9 ± 4.67     15.69 ± 2.36     0.81
  C.Ca (mmol/L) (mean ± SD)                             2.3 ± 0.15        2.32 ± 0.13     2.32 ± 0.12     2.34 ± 0.10      0.043
  Male, N (%)                                           56 (30.4%)        237 (43.3%)     67 (37.9%)      37 (40.2%)       0.019
  Female, N (%)                                         128 (69.6%)       310 (56.7%)     110 (62.1%)     55 (59.8%)       
  T1DM, N (%)                                           71 (38.6%)        209 (38.2%)     37 (20.9%)      21 (22.8%)       0.000017
  T2DM, N (%)                                           113 (61.4%)       338 (61.8%)     140 (79.1%)     71 (77.2%)       

HbA1c: glycated hemoglobin; TSH: thyroid-stimulating hormone; FT4: free thyroxine; C.Ca: corrected calcium; T1DM: type 1 diabetes mellitus; T2DM: type 2 diabetes mellitus.

Whether there is an association between 25(OH)D and HbA1c was investigated in the present study. The results showed that there was an inverse correlation between serum 25(OH) vitamin D and HbA1c (r (relationship coefficient) = -0.14, P \< 0.0000002) before supplementation with vitamin D. After supplementation with vitamin D, there was still an inverse correlation between serum 25(OH)D and HbA1c (r = -0.16, P \< 0.000001). There was an inverse correlation between 25(OH)D and HbA1c levels for each vitamin D group (\< 20 group, r = -0.14, P = 0.05; ≥ 20 and \< 50 group, r = -0.13, P = 0.001; ≥ 50 and \< 75 group, r = -0.04, P = 0.08; and ≥ 75 group, r = 0.04, P = 0.29); however, it was not significant for all groups. All these results show that there is some significant inverse correlation between serum 25(OH)D and HbA1c, as serum 25(OH)D goes up HbA1c comes down.

The mean HbA1c value was 10.62% in severe vitamin D deficiency, 10.86% in moderate vitamin D deficiency, 9.93% in vitamin D insufficiency and 9.81% in vitamin D sufficiency. After supplementation, we noticed significant reduction in the mean HbA1c values and improvement in mean vitamin D value ([Figs. 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}). The mean HbA1c value reduced to 7.63% in severe vitamin D deficiency, 7.89% in moderate vitamin D deficiency, 7.37% in vitamin D insufficiency, and 7.4% in vitamin D sufficiency ([Table 3](#T3){ref-type="table"}). After regrouping the patients into groups on the basis of their vitamin D levels, there were no patients in the severe deficiency group and most patients were in the sufficiency group and there was a significant difference between the groups (\< 0.00001) ([Table 4](#T4){ref-type="table"}).

![Vitamin D - baseline and follow-up.](jocmr-09-1013-g001){#F1}

![HbA1c - baseline and follow-up. HbA1c: glycated hemoglobin.](jocmr-09-1013-g002){#F2}

###### Mean Change of Vitamin D Levels and HbA1c at Follow-Up

  Vitamin D        n     Vitamin D baseline (mean ± SD)   HbA1c baseline (mean ± SD)   Vitamin D follow-up (mean ± SD)   HbA1c follow-up (mean ± SD)   Mean change vitamin D (P value)   Mean change HbA1c (P value
  ---------------- ----- -------------------------------- ---------------------------- --------------------------------- ----------------------------- --------------------------------- ----------------------------
  \< 20            184   14.17 ± 3.89                     10.62 ± 2.45                 68.11 ± 29.02                     7.63 ± 1.61                   +53.94 (0.0001)                   -2.99 (0.0001)
  ≥ 20 and \< 50   547   33.58 ± 8.23                     10.86 ± 2.6                  74.46 ± 25.84                     7.89 ± 1.7                    +40.88 (0.0001)                   -2.97 (0.0001)
  ≥ 50 and \< 75   177   60.33 ± 7.03                     9.93 ± 2.56                  92.27 ± 20.02                     7.37 ± 1.39                   +31.94 (0.0001)                   -2.56 (0.0001)
  ≥ 75             92    91.75 ± 15.14                    9.81 ± 2.52                  118.66 ± 31.12                    7.4 ± 1.16                    +26.91 (0.0001)                   -2.41 (0.0001)

HbA1c: glycated hemoglobin.

###### Coefficient of Correlation Between Groups

  Vitamin D        n     Vitamin D follow-up (mean ± SD)   HbA1c post-supplementation (mean ± SD)   Coefficient of correlation   P value
  ---------------- ----- --------------------------------- ---------------------------------------- ---------------------------- ---------
  ≥ 20 and \< 50   164   41.34 ± 5.35                      7.95 ± 1.70                              -0.02                        0.79
  ≥ 50 and \< 75   288   62.94 ± 7.33                      8.03 ± 1.84                              0                            0.97
  ≥ 75             548   101.5 ± 22.83                     7.46 ± 1.39                              -0.1                         0.02

HbA1c: glycated hemoglobin.

Discussion {#s5}
==========

In spite of the Middle East being sunny, we still find many studies reporting a deficiency in vitamin D levels among the population. A cross-sectional, school-based study carried out in all 13 regions of Saudi Arabia found 95.6% of adolescents were vitamin D deficient \[[@R06]\]. Another study found a majority of Saudi medical students (75.2%) had 25(OH)D levels \< 30 nmol/L, defined as risk for deficiency by the Institute of Medicine \[[@R07]\]. Vitamin D deficiency (25(OH)D \< 50 nmol/L) and insufficiency (25(OH)D = 50 -74 nmol/L) were reported in 50% and 43.8% in a study sample of pregnant women in a tertiary care center in Riyadh \[[@R08]\]. Our study reported similar findings where we found 73.1% of the patients had 25(OH)D levels \< 50 nmol/L. Even after supplementation, we found 16.4% of the patients had 25(OH)D levels \< 50 nmol/L.

An association between vitamin D levels and glycemic control has been reported in several studies, but the association is not consistent. Several animal and human studies suggest that vitamin D is a potential risk modifier for both types of diabetes \[[@R9], [@R10]\]. Some studies conclude that vitamin D has a direct effect in improved insulin secretion and insulin action, and subsequently, improved glucose homeostasis through activation of the vitamin D receptor on the β-cell of the pancreas islet of Langerhans \[[@R11]\]. Other studies suggest vitamin D has an indirect role via regulation of calcium homeostasis on various mechanisms (like pancreatic beta-cell dysfunction, impaired insulin action and systemic inflammation) related to the pathophysiology of both types of diabetes \[[@R12]\].

A systematic review and meta-analysis reported that vitamin D and calcium insufficiency may negatively influence glycemia and that a combined supplementation of vitamin D and calcium may optimize glucose metabolism \[[@R11]\]. Another systematic review and meta-analysis reported a lower risk for developing type 1 diabetes with self-reported vitamin D supplementation in early childhood (odds ratio: 0.71, 95% confidence interval (CI): 0.60 - 0.84) \[[@R13]\]. A meta-analysis of several prospective studies showed an inverse and significant association between circulating 25(OH)D levels and risk of type 2 diabetes across a broad range of blood 25(OH)D levels in diverse populations \[[@R14]\]. A study from Italy showed HbA1c is inversely related to serum vitamin D levels in type 2 diabetes patients (r = -0.116, P = 0.003) \[[@R15]\]. Our study also found HbA1c to be inversely related to serum vitamin D levels (r = -0.14, P \< 0.0000002 before supplementation and r = -0.16, P \< 0.000001 after supplementation with vitamin D).

A study from Iran showed that HbA1c may be reduced by administration of vitamin D to children and adolescents with type 1 DM without changing the dose of insulin \[[@R16]\]. A 3-year study done in the US found a significant reduction in HbA1c levels from year 1 to year 2 and between year 1 and year 3 after supplementation of vitamin D in type 2 African American diabetic patients \[[@R17]\]. A study done in Saudi Arabia reported that there was an observed effect after 12 weeks of vitamin D supplementation on glycemic control in vitamin D - replete, type 1 DM patients \[[@R18]\]. Our study concurs with all these studies and we observed lowering of HbA1c after supplementation of vitamin D ([Table 3](#T3){ref-type="table"}).

Another systematic review done on 29 randomized control trials (3,324 participants) that assessed the relationship between vitamin D supplementation and change in HbA1c and fasting blood glucose (FBG) among adults with type 2 diabetes found there was a modest reduction in HbA1c (-0.32% (-0.53 to -0.10), I^2^ = 91.9%) compared to placebo after vitamin D supplementation \[[@R19]\]. In studies achieving repletion of vitamin D deficiency (n = 7), there were greater mean reductions in HbA1c (-0.45% (-1.09 to 0.20)) and FBG (-7.64 mg/dL (-16.25 to 0.97)) although not significant.

A recent systematic review and meta-analysis of relevant prospective studies till January 2017 was studied to determine the effect of vitamin D supplementation and improved vitamin D status on glycemia and insulin resistance in type 2 diabetic patients \[[@R20]\]. From a total of 844 entries identified via literature search, 24 controlled trials (1,528 individuals diagnosed with type 2 diabetes) evaluating the impact of vitamin D supplementation on HbA1c, serum fasting plasma glucose (FPG), and homeostatic model assessment of insulin resistance (HOMA-IR) in diabetic patients were included.

The meta-analysis indicated a significant reduction in HbA1c (mean difference: -0.30%; 95% CI: -0.45 to -0.15, P \< 0.001), FPG (mean difference: -4.9 mg/dL (-0.27 mmol/L); 95% CI: -8.1 to -1.6 (-0.45 to -0.09 mmol/L), P = 0.003), and HOMA-IR (mean difference: -0.66; 95% CI: -1.06 to -0.26, P = 0.001) following vitamin D supplementation and significant increase in serum 25(OH)D levels (overall increase of 17 ± 2.4 ng/mL (42 ± 6 nmol/L)).

The meta-analysis concluded that a minimum dose of 100 µg/day (4,000 IU/day) of vitamin D supplementation may significantly reduce serum FPG, HbA1c, and HOMA-IR index, and helps to control glycemic response and improve insulin sensitivity in type 2 diabetic patients \[[@R20]\].

Our study strongly concurs with these systematic reviews as we also found that there was a significant reduction in HbA1c (mean difference: -2.848%; 95% CI: -3.04 to -2.66, P \< 0.001).

The need of accurate and precise measurement of blood glucose has made HbA1c become the gold standard for monitoring glycemic control in patients with DM from primarily fasting plasma \[[@R21]\]. Endorsement of influential diabetes societies and the World Health Organization for using HbA1c as a diagnostic test for diabetes arose due to the clear advantages for HbA1c over glucose monitoring (and in particular oral glucose tolerance test (OGTT)) \[[@R22]\]. Vitamin D supplementation to help reduce HbA1c values will result in overall better health and improve glycemic outcomes in patients with diabetes. Our study also noted that the group with better vitamin D levels were older maybe due to better diet and lifestyle pattern (P = 0.0001). Poor diet, less time spent outdoors, and the consumption of more processed food by the younger generation can be a major contributor to their lower vitamin D levels.

Improvement in diet or vitamin D supplementation with added exposure to sunlight at the optimal sun exposure time \[[@R23]\] may improve vitamin D levels with additional benefit to the patient's overall health.

Conclusions {#s5a}
-----------

In conclusion, there is a significant inverse association between serum 25(OH)D and HbA1c. The important result we find from this study is a significant reduction in HbA1c as vitamin D levels increased. The percentage of vitamin D deficiency in the population and the growth of diabetes in the population suggest that repletion can improve overall health. There is so much benefit to be gotten from supplementation with vitamin D or by adding natural vitamin D rich food in the diet and including physical activities with possible sun light exposure. Advising patients with higher HbA1c to get tested for lower vitamin D values and correct any deficiency if found may result in better blood glucose control and benefit the patient's overall health.
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